Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Prebet

Showing results (61-70 of 99) with videos related to

Pageof 10
Sort By:
Cancer|April 15, 2025
Real-world treatment patterns and outcomes with oral azacitidine maintenance therapy in patients with acute myeloid leukemiaBrian Leber, Marcia T Ruiz, Hany Elgendy, et al.
Journal of Cellular and Molecular Medicine|December 21, 2016
Acquired TET2 mutation in one patient with familial platelet disorder with predisposition to AML led to the development of pre-leukaemic clone resulting in T2-ALL and AML-M0Vladimir T Manchev, Hind Bouzid, Iléana Antony-Debré, et al.
British Journal of Haematology|April 25, 2009
Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemiaVéronique Gelsi-Boyer, Virginie Trouplin, José Adélaïde, et al.
Cancer Research|March 11, 2016
Frequency and Dynamics of Leukemia-Initiating Cells during Short-term Ex Vivo Culture Informs Outcomes in Acute Myeloid Leukemia PatientsEmmanuel Griessinger, Fernando Anjos-Afonso, Jacques Vargaftig, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 17, 2014
Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantationRaynier Devillier, Samia Harbi, Sabine Fürst, et al.
Experimental Hematology|September 21, 2010
Reduced-intensity conditioning with Fludarabin, oral Busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignanciesDidier Blaise, Laure Farnault, Catherine Faucher, et al.
Haematologica|December 31, 2016
Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the <i>Groupe Francophone Des Myélodysplasies</i>Lionel Ades, Thomas Prebet, Aspasia Stamatoullas, et al.
Blood|June 4, 2016
Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapyRuxanda Moschoi, Véronique Imbert, Marielle Nebout, et al.
Blood|November 7, 2008
Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 studyLionel Adès, Simone Boehrer, Thomas Prebet, et al.
Leukemia|March 11, 2022
In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2Rana Gbyli, Yuanbin Song, Wei Liu, et al.
Pageof 10

Showing results (61-70 of 99) with videos related to

Sort By:
Pageof 10
Cancer|April 15, 2025
Real-world treatment patterns and outcomes with oral azacitidine maintenance therapy in patients with acute myeloid leukemiaBrian Leber, Marcia T Ruiz, Hany Elgendy, et al.
Journal of Cellular and Molecular Medicine|December 21, 2016
Acquired TET2 mutation in one patient with familial platelet disorder with predisposition to AML led to the development of pre-leukaemic clone resulting in T2-ALL and AML-M0Vladimir T Manchev, Hind Bouzid, Iléana Antony-Debré, et al.
British Journal of Haematology|April 25, 2009
Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemiaVéronique Gelsi-Boyer, Virginie Trouplin, José Adélaïde, et al.
Cancer Research|March 11, 2016
Frequency and Dynamics of Leukemia-Initiating Cells during Short-term Ex Vivo Culture Informs Outcomes in Acute Myeloid Leukemia PatientsEmmanuel Griessinger, Fernando Anjos-Afonso, Jacques Vargaftig, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 17, 2014
Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantationRaynier Devillier, Samia Harbi, Sabine Fürst, et al.
Experimental Hematology|September 21, 2010
Reduced-intensity conditioning with Fludarabin, oral Busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignanciesDidier Blaise, Laure Farnault, Catherine Faucher, et al.
Haematologica|December 31, 2016
Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the <i>Groupe Francophone Des Myélodysplasies</i>Lionel Ades, Thomas Prebet, Aspasia Stamatoullas, et al.
Blood|June 4, 2016
Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapyRuxanda Moschoi, Véronique Imbert, Marielle Nebout, et al.
Blood|November 7, 2008
Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 studyLionel Adès, Simone Boehrer, Thomas Prebet, et al.
Leukemia|March 11, 2022
In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2Rana Gbyli, Yuanbin Song, Wei Liu, et al.
Pageof 10